Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034203 | Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis. | PHASE2 | COMPLETED | - | — | — | Apr 1, 2002 | Aug 1, 2003 | Jun 24, 2005 | 52 | United States |
| Name | Type | Description |
|---|---|---|
| efalizumab | DRUG | - |
Inclusion criteria: * Clinical diagnosis of moderate to severe rheumatoid arthritis. * On stable dose of methotrexate. * 18 to 80 years of age. * Less than 275 lbs. Exclusion criteria: * Joint replacement surgery within 60 days of the start of drug dosing. * Intra-articular cortisone injections w...